Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study

References

• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436. doi: 10.1056/NEJMra040291.
   PubMed Web of Science ®Google Scholar
• Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the armadale echocardiography cohort. Heart. 2012;98(24):1805–1811. doi: 10.1136/heartjnl-2012-301992.
   PubMed Web of Science ®Google Scholar
• The Pharmaceutical Benefits Scheme. Pulmonary arterial hypertension (PAH) medicines utilisation analysis. Sydney, Australia: The Pharmaceutical Benefits Scheme Drug Utilisation Sub-committee; 2015. [cited 2023 May 19]. Available from: http://www.pbs.gov.au/industry/listing/participants/public-release-docs/pulm-art-hypertension/pulmonary-arterial-hypertension-dusc-prd-2015-02-final.pdf.
   Google Scholar
• Anderson J, Lavender M, Lau E, et al. Pharmacological treatment of pulmonary arterial hypertension in Australia: current trends and challenges. Heart Lung Circ. 2020;29(10):1459–1468. doi: 10.1016/j.hlc.2020.01.017.
   PubMed Web of Science ®Google Scholar
• Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844. doi: 10.1056/NEJMoa1413687.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Wang N, Gu ZC, et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2019;9(3):239–249. doi: 10.21037/cdt.2019.03.02.
   PubMed Web of Science ®Google Scholar
• Gao XF, Zhang JJ, Jiang XM, et al. Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. Patient Prefer Adherence. 2017;11:871–885. doi: 10.2147/PPA.S133288.
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537. doi: 10.1093/eurheartj/ehp297.
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi: 10.1093/eurheartj/ehac237.
   PubMed Web of Science ®Google Scholar
• Lin H, Wang M, Yu Y, et al. Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: a network meta-analysis. Pulm Pharmacol Ther. 2018;50:1–10. doi: 10.1016/j.pupt.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Wang S, Yu M, Zheng X, et al. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018;25(1):1898–1909. doi: 10.1080/10717544.2018.1523257.
   PubMed Web of Science ®Google Scholar
• Frantz RP, Hill JW, Lickert CA, et al. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. Pulm Circ. 2020;10(1):2045894019880086. doi: 10.1177/2045894019880086.
   Web of Science ®Google Scholar
• Hull M, Pruett J, Koep E, et al. Treatment patterns and medication adherence and persistence among patients with pulmonary arterial hypertension in a real-world database representing a large US health plan. Paper presented at: 22nd Annual ISPOR International Meeting; 2017 May 20–24; Boston, MA.
   Google Scholar
• Grady D, Weiss M, Hernandez-Sanchez J, et al. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulm Circ. 2018;8(1):2045893217743616. doi: 10.1177/2045893217743616.
   Web of Science ®Google Scholar
• Studer S, Hull M, Pruett J, et al. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulm Circ. 2019;9(1):2045894018816294. doi: 10.1177/2045894018816294.
   Web of Science ®Google Scholar
• Shah NB, Mitchell RE, Proctor ST, et al. High rates of medication adherence in patients with pulmonary arterial hypertension: an integrated specialty pharmacy approach. PLoS One. 2019;14(6):e0217798. doi: 10.1371/journal.pone.0217798.
   PubMed Web of Science ®Google Scholar
• Waxman A, Chen SY, Boulanger L, et al. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Econ. 2013;16(2):298–306. doi: 10.3111/13696998.2012.756399.
   PubMedGoogle Scholar
• Jain S, Khera R, Girotra S, et al. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest. 2017;151(1):90–105. doi: 10.1016/j.chest.2016.08.1461.
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786.
   PubMed Web of Science ®Google Scholar
• Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–490. doi: 10.1111/j.1365-2796.2004.01405.x.
   PubMed Web of Science ®Google Scholar
• Mandras SA, Gilkin RJ, Jr, Pruett JA, et al. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care. 2014;20(9):S191–S199.
   PubMed Web of Science ®Google Scholar
• Kjellström B, Sandqvist A, Hjalmarsson C, et al. Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2020;6(4):00299-2020. doi: 10.1183/23120541.00299-2020.
   PubMedGoogle Scholar
• Leo S, Liu Y, Brown-Gentry B, et al. Utilization and adherence rates to pulmonary arterial hypertension medications. Paper presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting; 2017 March 27–30; Denver, CO.
   Google Scholar
• Tatius B, Wasityastuti W, Astarini FD, et al. Significance of BMPR2 mutations in pulmonary arterial hypertension. Respir Investig. 2021;59(4):397–407. doi: 10.1016/j.resinv.2021.03.011.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Pausch C, Grünig E, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020;39(12):1435–1444. doi: 10.1016/j.healun.2020.09.011.
   PubMed Web of Science ®Google Scholar
• Hayes D. Jr. Idiopathic pulmonary arterial hypertension misdiagnosed as asthma. J Asthma. 2007;44(1):19–22. doi: 10.1080/02770900601125243.
   PubMed Web of Science ®Google Scholar
• Deaño RC, Glassner-Kolmin C, Rubenfire M, et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med. 2013;173(10):887–893. doi: 10.1001/jamainternmed.2013.319.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Dwivedi K, Pausch C, et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med. 2022;10(10):937–948. doi: 10.1016/S2213-2600(22)00097-2.
   PubMed Web of Science ®Google Scholar